FIRST ADVANTAGE CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FIRST ADVANTAGE CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $860.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $763.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $810.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $712.30M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $472.37M | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | $36.79M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $481.77M | Mar 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.82M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($110.27M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $37.29M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $64.60M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $16.05M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($47.49M) | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | ($36.53M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $34.25M | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($62.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $81.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $94.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $63.82M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($2.04M) | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | ($9.0K) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $92.17M | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.85M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $63.82M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $49.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $51.93M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $45.51M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $32.20M | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | $3.19M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $33.24M | Mar 23, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $263.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $116.73M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $116.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $107.98M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $66.86M | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | $11.24M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $85.08M | Mar 23, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.13M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $28.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $162.82M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $212.77M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $148.68M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $72.85M | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | ($19.22M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $71.58M | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $6.17M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $7.31M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.30M | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | $951.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $6.58M | Mar 23, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.83B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.92B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.63B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.89B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.89B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.76B | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.52B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.62B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $723.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $759.21M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $754.34M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $969.42M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.31B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.31B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $906.73M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.13B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $794.27M | Mar 23, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.14B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.12B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $820.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $793.08M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $793.89M | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | $770.09M | Mar 23, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($194.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($159.81M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($49.55M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($27.36M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($31.44M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($47.49M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $168.69M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $213.77M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $391.66M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $292.64M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $152.82M | Mar 23, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.16B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $564.72M | Feb 27, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2022 | Jan 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 174.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 173.17M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 145.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 148.73M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 152.90M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 130.00M | Mar 23, 2022 |